All Stories

  1. B cells and atherosclerosis in systemic lupus erythematosus
  2. TNFAIP3 F127C Coding Variation in Greek Primary Sjogren’s Syndrome Patients
  3. Fatigue in Primary Sjögren's Syndrome: Clinical, Laboratory, Psychometric, and Biologic Associations
  4. Clinical and Laboratory Predictors of Distinct Histopathogical Features of Lupus Nephritis
  5. Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren’s syndrome: prevalence, clinical and laboratory associations
  6. Predicting the Outcome of Sjogren’s Syndrome-Associated Non-Hodgkin’s Lymphoma Patients
  7. Sjögren’s Syndrome
  8. SAT0023 Clinical and Laboratory Predictors of Distinct Histological Classes of Lupus Nephritis-Can They Substitute the Renal Biopsy?
  9. THU0243 Proper Initiation of Biologic Treatment (TREAT-TO-TARGET STRATEGY) Favors Better Outcome in Patients with Rheumatoid Arthritis
  10. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome
  11. SAT0128 Biologic Treatment is Associated with More Serious Adverse Reactions, Serious Infections and Admissions in Hospital than DMARDS in Patients with Rheumatoid Arthritis: A REAL World Study
  12. FRI0001 Good Response after Three Months of Treatment with Biologic Agents May PREDICT Long-Term Efficacy of Biologic Treatment in Patients with Rheumatoid Arthritis
  13. Elevated IgG4 Serum Levels Among Primary Sjögren's Syndrome Patients: Do They Unmask Underlying IgG4-Related Disease?
  14. Sjogren syndrome
  15. Sjögren's Syndrome
  16. Sjögren’s Syndrome
  17. Sjögren’s Syndrome
  18. Absence of somatic MYD88 L265P mutations in patients with primary Sjogren’s syndrome
  19. New advances in the classification, pathogenesis and treatment of Sjogrenʼs syndrome
  20. THU0325 Elevated IgG4 Serum Levels Among Primary Sjogren’s Syndrome Patients: Do they Unmask Underlying IgG4-Related Disease?
  21. THU0012 BAFF Genetic Variants in Lymphomagenesis Associated with Sjogren’s Syndrome
  22. AB0233 Type I interferon and clinical phenotype in idiopathic inflammatory myopathies
  23. THU0137 Effectiveness and Adverse Reactions of Long-Term Use of Biologic Agents in Patients with Rheumatoid Arthritis: A Retrospective Study
  24. Treatment of dry eyes in Sjögren's syndrome: the role of autologous blood serum
  25. Increased Serum Type I Interferon Activity in Organ-Specific Autoimmune Disorders: Clinical, Imaging, and Serological Associations
  26. Endocrine alterations in primary Sjogren's syndrome: An overview
  27. Brief Report: Adrenal autoimmunity in primary Sjögren's syndrome
  28. Ocular actions of platelet-activating factor: clinical implications
  29. Linear IgA dermatosis in a patient with primary Sjogren's syndrome
  30. Cytotoxics or biologicals in the treatment of Sjögren’s syndrome?
  31. Adult Onset Still's Disease and Autoinflammation
  32. Adult-Onset Still’s Disease: From Pathophysiology to Targeted Therapies
  33. Autoimmune Disorders - Pathogenetic Aspects
  34. Subclinical Atherosclerosis in Systemic Autoimmune Disorders
  35. Activation of the type I interferon pathway in primary Sjögrenʼs syndrome
  36. Role of Asymmetrical Dimethylarginine in Inflammation-Induced Endothelial Dysfunction in Human Atherosclerosis
  37. Increased prevalence of anti-thyroid antibodies in patients with limited scleroderma
  38. Cardiovascular Involvement
  39. Pulmonary Involvement
  40. Classic Immunosuppressive and Immunomodulatory Drugs
  41. Activation of Type I Interferon Pathway in Systemic Lupus Erythematosus: Association with Distinct Clinical Phenotypes
  42. Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome
  43. Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study
  44. Activation of the type I interferon pathway in primary Sjogren’s syndrome
  45. Psychopathological and personality features in primary Sjogren's syndrome--associations with autoantibodies to neuropeptides
  46. The geoepidemiology of Sjögren's syndrome
  47. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-β/α ratios in rheumatoid arthritis patients: A post hoc analysis of a predominantly Hispanic cohort
  48. Antithyroid antibodies in antiphospholipid syndrome: prevalence and clinical associations
  49. Increased Prevalence of Antibodies to Thyroid Peroxidase in Dry Eyes and Mouth Syndrome or Sicca Asthenia Polyalgia Syndrome
  50. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies
  51. Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade
  52. Stress, coping strategies and social support in patients with primary Sjögren’s syndrome prior to disease onset: a retrospective case–control study
  53. Sa.18. The Type I IFN Signature Determines the Sustained Anti-citrullinated Protein Antibody Levels During TNFα Blockade in Rheumatoid Arthritis
  54. Sa.23. Nucleosomes, but Not Type I Interferons, Contribute to the Induction of Anti-nuclear Antibodies by TNF Alpha Blockade in Spondyloarthritis
  55. Augmented interferon-α pathway activation in patients with Sjögren's syndrome treated with etanercept
  56. Conventional Therapy of Sjogren’s Syndrome
  57. Activation of type I interferon in systemic lupus erythematosus
  58. A novel mutation of the familial Mediterranean fever gene in a Greek family related to a non-classical, variably expressed FMF phenotype
  59. Rheumatoid arthritis: correlation between rheumatoid factor levels and CA-125 tumour marker elevation
  60. Analysis ofSAA1gene polymorphisms in the Greek population: rheumatoid arthritis and FMF patients relative to normal controls. Homogeneous distribution and low incidence of AA amyloidosis
  61. Systemic Autoimmune Manifestations: When Should Underlying Thyroid Autoimmunity be Considered?
  62. The management of Sjögren's syndrome
  63. Infliximab in Takayasu arteritis: a safe alternative?
  64. Retroperitoneal fibrosis and c-ANCA positivity
  65. Alleviation of polyarticular syndrome in multicentric reticulohistiocytosis with intravenous zoledronate
  66. Is polydipsia sometimes the cause of oxcarbazepine-induced hyponatremia?
  67. Immunsuppression und Immunmodulation beim Sjögren-Syndrom - Was ist bewiesen? Lindert sie die Sicca-Symptome?
  68. A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion
  69. Anti-CD40 antibodies in antiphospholipid syndrome and systemic lupus erythematosus
  70. Nervous System Involvement in Sjogren's Syndrome
  71. Cutaneous ulcers: An unusual manifestation of inherited thrombophilia
  72. Lupus nephritis: current issues
  73. Pure red cell aplasia in a Sjögren's syndrome/lupus erythematosus overlap patient
  74. Sjögren’s Syndrome: Autoantibodies to Cellular Antigens
  75. Recurrent pregnancy loss and autoantibody profile in autoimmune diseases
  76. Rheumatoid arthritis in the elderly
  77. Pregnancy outcome and anti-Ro/SSA in autoimmune diseases: a retrospective cohort study